Immune therapy targets cells that cause leukemia relapse
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study. The new cell therapy, now being tested in phase 1 clinical trials, may ultimately help patients with AML to remain cancer-free.
Materials provided by Weill Cornell Medicine. Note: Content may be edited for style and length.
Source link aaaaa